Current status specifiers for patients at clinical high risk for psychosis  by Woods, Scott W. et al.
Schizophrenia Research 158 (2014) 69–75
Contents lists available at ScienceDirect
Schizophrenia Research
j ourna l homepage: www.e lsev ie r .com/ locate /schresCurrent status speciﬁers for patients at clinical high risk for psychosisScott W. Woods a,⁎, Barbara C. Walsh a, Jean Addington b, Kristin S. Cadenhead c, Tyrone D. Cannon d,
Barbara A. Cornblatt e, Robert Heinssen f, Diana O. Perkins g, Larry J. Seidman h, Sarah I. Tarbox a,
Ming T. Tsuang c,h, Elaine F. Walker i, Thomas H. McGlashan a
a Department of Psychiatry, Yale University, New Haven, CT, United States
b Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada
c Department of Psychiatry, UCSD, San Diego, CA, United States
d Department of Psychology, Yale University, New Haven, CT, United States
e Department of Psychiatry, Zucker Hillside Hospital, Long Island, NY, United States
f Division of Services and Intervention Research, National Institute of Mental Health, Bethesda, MD, United States
g Department of Psychiatry, University of North Carolina, Chapel Hill, NC, United States
h Department of Psychiatry, Harvard Medical School, Boston, MA, United States
i Departments of Psychology and Psychiatry, Emory University, Atlanta, GA, United States⁎ Corresponding author at: PRIME Research Clinic for
Department of Psychiatry, Yale University School of Med
CT 06519, United States. Tel.: +1 203 974 7038.
E-mail address: scott.woods@yale.edu (S.W. Woods).
http://dx.doi.org/10.1016/j.schres.2014.06.022
0920-9964/© 2014 Published by Elsevier B.V.a b s t r a c ta r t i c l e i n f oArticle history:
Received 31 March 2014
Received in revised form 2 June 2014
Accepted 8 June 2014
Available online 8 July 2014
Keywords:
Psychosis
Clinical high risk
Risk syndrome
Current status
Course of illness
Background: Longitudinal studies of the clinical high risk (CHR) syndrome for psychosis have emphasized the
conversion vs non-conversion distinction and thus far have not focused intensively on classiﬁcation among
non-converters. The present study proposes a system for classifying CHR outcomes over time when using the
Structured Interview for Psychosis-risk Syndromes and evaluates its validity.
Method: The system for classifying CHR outcomes is referred to as “current status speciﬁers,” with “current”
meaning over themonth prior to the present evaluation and “speciﬁers” indicating a set of labels and descriptions
of the statuses. Speciﬁers for four current statuses are described: progression, persistence, partial remission, and
full remission. Data from the North American Prodromal Longitudinal Study were employed to test convergent,
discriminant, and predictive validity of the current status distinctions.
Results: Validity analyses partly supported current status distinctions. Social and role functioning were more im-
paired in progressive and persistent than in remitted patients, suggesting a degree of convergent validity. Agree-
ment between CHR current statuses and current statuses for a different diagnostic construct (DSM-IV Major
Depression) was poor, suggesting discriminant validity. The proportion converting to psychosis within a year
was signiﬁcantly higher in cases meeting progression criteria than in those meeting persistence criteria and
tended to be higher than in those meeting full remission criteria, consistent with a degree of predictive validity.
Discussion: CHR syndrome current status speciﬁers could offer a potentially valid and useful description of cur-
rent clinical status among non-converters. Study in additional samples is needed.
© 2014 Published by Elsevier B.V.1. Introduction
Aprodromal period before the onset of frank schizophrenia has been
recognized for at least a century (Bleuler, 1911; Klosterkotter et al.,
2008), and over the past two decades a growing body of work has
sought to diagnose a prodromal syndrome prospectively (Fusar-Poli
et al., 2013). One approach has been to deﬁne clinical high risk (CHR)
criteria, also known as at-riskmental state or ultra-high risk or risk syn-
drome (Schultze-Lutter et al., 2011) criteria. Two structured diagnosticthe Psychosis Risk Syndrome,
icine, 34 Park St., New Haven,interviews, the Comprehensive Assessment of At Risk Mental States
(CAARMS) (Yung et al., 2004) and the Structured Interview for
Psychosis-risk Syndromes (SIPS) (McGlashan et al., 2010) have demon-
strated reliability and validity (Yung et al., 2005; Addington et al., 2007;
Yung et al., 2008; Woods et al., 2009, 2010; Fusar-Poli et al., 2012b).
While CHR criteria consistently have been statistically signiﬁcant
predictors of conversion, it has becomemore clear over the past decade
that themajority of patientsmeeting the criteria do not go on to become
psychotic (Cannon et al., 2008; Ruhrmann et al., 2010; Fusar-Poli et al.,
2012a; Nelson et al., 2013). Some of the non-converting patients remain
symptomatic over time, and others become symptom-free (Addington
et al., 2011). At present, however, existing diagnostic criteria have
paid relatively little attention to follow-up classiﬁcation.
This paper proposes a new classiﬁcation system for CHR patients
when using the SIPS over time. The system is based on diagnostic
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rent status that may vary over follow-up. Data from the ﬁrst phase of
the North American Prodrome Longitudinal Study (Addington et al.,
2007) (NAPLS-1) are used to evaluate the validity of the current status
distinctions.
2. Methods
In the term “current status speciﬁers,” “current” refers to the month
prior to the present evaluation and “speciﬁers” to a set of labels and de-
scriptions of possible statuses. Although conversion to psychosis could
also be considered a current status, the focus of the present paper is
not upon the existing SIPS deﬁnition of conversion but on new speciﬁers
of current status for patients who have not converted or who have not
converted yet. The proposed current status speciﬁers are inﬂuenced
by the severity/psychosis/remission speciﬁers used for affective disor-
der diagnoses (American Psychiatric Association, 1987, 1994, 2013)
and remission criteria proposed for schizophrenia (van Os et al., 2006).
2.1. Current status speciﬁers
The SIPS identiﬁes three CHR syndromes: Attenuated Psychotic
Symptoms Syndrome (APSS), Brief Intermittent Psychosis Syndrome
(BIPS), and Genetic Risk and Deterioration (GRD), all originally articu-
lated by the Melbourne group (Yung et al., 1996). In previous versions
of the SIPS, criteria for each CHR syndrome required recent worsening,
and each was scored only as currently present vs not currently present.
Differentways of notmeeting currentworsening criteria (features pres-
ent but no longer worsening, features no longer present, features never
present) were not distinguished.
For each CHR syndrome Fig. 1 outlines criteria for four current status
speciﬁers: progression, persistence, partial remission, and full remission.
The current status speciﬁers may be applied to patients meeting
syndromal diagnostic criteria, also in Fig. 1. The syndromal criteria and
the current status speciﬁers are intended to be used together, at initial
evaluation and/or at any follow-up assessment. The syndromal diagnosis
would apply across course while the current status could vary (for exam-
ple: APSS currently progressive, or GRD currently in partial remission).
Fig. 1 shows that for APSS and BIPS a CHR diagnosis depends on a
history of at least one positive symptom meeting severity, frequency,
and attribution criteria. APSS or BIPS progression requires that these
criteria be met currently as well as recent worsening: these APSS or
BIPS progression criteria are identical to our previously proposed SIPS
criteria for APSS and BIPS current presence yes vs no. APSS or BIPSTerm Defined APSS Syndrome
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Fig. 1. Deﬁnitions for clinical high risk syndrome and current status speciﬁers when using the S
Symptoms Syndrome, BIPS—Brief Intermittent Psychosis Syndrome, GRD—Genetic Risk and fun
sonality disorder, Hx—history of, GAF—Global Assessment of Functioning. N.B.When a patient w
higher level than another (e.g. both APSS progressive and GRD persistent), the higher level curr
persistence trumps partial remission trumps full remission”.persistence are similar to APSS or BIPS progression in requiring that
syndromal criteria bemet currently but differ in that worsening criteria
cannot. For APSS or BIPS partial remission two pathways were consid-
ered appropriate, following the format for DSM affective disorders in
partial remission. For the ﬁrst pathway, no positive symptom can
meet severity and attribution criteria, but for no longer than 6 months.
For the second pathway, one or more positive symptoms do currently
meet severity and attribution criteria but not frequency criteria. Patients
meeting criteria for this second route could potentially remain in partial
remission for an indeﬁnite period of time. For APSS or BIPS full remis-
sion, no positive symptom has met severity and attribution criteria for
longer than 6 months. GRD syndromal and current status criteria are
based on indices of genetic risk and changes in global functioning.
Criteria for GRD progression differ slightly from our previous criteria
for GRD current presence (rationale in Supplementary data).
When patients meet criteria for a current status for one CHR syn-
drome (e.g. GRD partial remission) but also criteria for a different cur-
rent status for another CHR syndrome (e.g. APSS progression), the
overall CHR syndrome current status is deﬁned according to the rule
“progression trumps persistence trumps partial remission trumps full
remission.” The supplementary data include pages fromSIPS 5.6 provid-
ing detail on how syndromal assessments and current status assess-
ments are scored.
2.2. Subjects
NAPLS-1 methods have been described in detail previously
(Addington et al., 2007). All subjects provided written informed con-
sent, and protocols were approved by institutional review boards at
each site. Symptomatic subjects from three groups according to the ear-
lier classiﬁcation (Woods et al., 2009)were eligible for the present anal-
yses if all 5 SIPS positive symptoms were rated for severity either at
baseline, 6 months, and 12 months or at 12, 18, and 24 months. Fig. 2
shows the ﬂow diagram of eligible subjects and reasons for ineligibility.
2.3. Classiﬁcation
Eligible subjects were then classiﬁed at each timepoint based as
closely as possible on the current status speciﬁer scheme shown in
Fig. 1. NAPLS-1 data, however, were not collected prospectively to
map onto this criterion set, and therefore certain criteria either could
not be applied or required estimation methods. Early versions of the
SIPS did not provide for symptom speciﬁc frequency ratings, and there-
fore symptom frequency datawere unavoidablymissing for some cases.BIPS Syndrome GRD Syndrome
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Fig. 2. Subjectﬂowdiagram of NAPLS-1 sample in the present analysis. Classiﬁcations shown at baselinewith the Structured Interview for Psychosis-risk Syndromes (SIPS) under the orig-
inal classiﬁcation scheme and for assessments as per thepresent paper for syndromal diagnosis and current status speciﬁcation, at baseline, one year, and two years. CHR—clinical high risk,
SPD—schizotypal personality disorder, PROG—progressive current status of CHR syndrome, No FU—no follow-up classiﬁcation possible, no end—did not have a study visit at the endpoint
of the one-year interval, no mid—did not have a study visit at the midpoint of the one-year interval, msg data—study visits occurred but severity data for one or more positive symptoms
were missing, PERS—persistent current status of CHR syndrome, Unk—unknown CHR history, PSYCH—transitioned to frank psychosis, PART—partial remission current status of CHR syn-
drome, FULL—full remission current status of CHR syndrome, Smf—currently symptomatic but cannot be classiﬁed as PROG vs PERS vs PART due to missing symptom frequency data.
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data) and sowas not the preferred option. To avoid such bias, we placed
symptomatic but missing frequency cases into a separate “Smf” catego-
ry (see Fig. 2).We thenmade use of data from the symptomatic patients
who did have frequency ratings (Table S1) to estimate percentages for
current status speciﬁers among the Smf group, as detailed in the Supple-
mentary data.
Ratings of symptom causal attribution were not added to the SIPS
until after NAPLS-1 data collection ended, and thus these data were
never collected and this requirement had to be waived.
Progression for APSS and GRD at follow-up was assessed by direct
comparison of ratings to those from one year previously. Evaluation of
BIPS progression criteria utilized ﬁelds in the SIPS that asked whether
positive symptoms had progressed to a 6 in the past 3 months.2.4. Validity
We investigated the validity of the current status speciﬁers in three
analyses. A convergent validity analysis asked whether social or role
functioning differed across current status. The social and role function-
ing variables (Cornblatt et al., 2007) did not contribute to the CHRsyndrome diagnosis or to the current status speciﬁer deﬁnitions. A dis-
criminant validity analysis evaluated the degree to which CHR current
status was independent from DSM-IV current status speciﬁers for co-
morbid major depression. Among comorbidities in CHR patients
(Rosen et al., 2006; Woods et al., 2009; Salokangas et al., 2012;
Fusar-Poli et al., 2014), major depression is perhaps the most frequent
and among the most severe and also is described by established
(American Psychiatric Association, 1994, 2013) current status speciﬁers.
Lastly, predictive validity analyses askedwhether the rate of conversion
to psychosis during a 12-month interval differed by current status at in-
terval start. We chose 12 months as the shortest interval whose out-
come did not depend on unmeasured information, such as positive
symptom or GAF data before baseline. The starting points of each avail-
able 12-month interval were lined up to provide a “snapshot” of the 12-
month conversion rate.2.5. Effects of treatment on conversion or progression after remission
In theNAPLS-1 cohort, some patients received psychotropicmedica-
tion or psychosocial treatment, either clinically during naturalistic re-
search follow-along or in prospective research trials, as previously
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2010; Woods et al., 2013). We thus also investigated the extent to
which cases converting or meeting progression criteria after having
achieved remission could potentially be accounted for by discontinua-
tion of treatment.
2.6. Statistical methods
Analyses were conducted using SPSS, version 19. Convergent validi-
ty analyses employed one-way ANOVA, with post-hoc pairwise testing
by Student's t-test. Discriminant validity analyses employed Cohen's
kappa. Predictive validity analyses utilized Fisher's exact tests.
3. Results
3.1. Availability of data
The NAPLS-1 database contains 624 symptomatic nonpsychotic pa-
tients at baseline (Woods et al., 2009). Of these, 435 (70%, see Fig. 2)
were classiﬁable according to Fig. 1, including 58 who met the criteria
for persistence at baseline. At one year, 172/435 were classiﬁable
(40%) and at two years, 44/172 (26%). The primary reason for the inabil-
ity to classify at baseline was that the information collected did not per-
mit identiﬁcation of whether CHR had ever been present before
baseline. The primary reason at follow-up was the absence of visits
(Fig. 2). Differences between the present sample and samples in other
reports on theNAPLS-1 cohort are discussed in the Supplementary data.
3.2. Current status determinations for individual CHR syndromes
Table S2 shows the degree of overlap between current status speci-
ﬁers for the three CHR syndromes among visits that ended intervals in
Fig. 2. As in previous studies the large majority of patients met criteria
for APSS. In the relatively few cases where more than one syndrome
was present, the current statuses agreed about 40% of the time, with
the “trumps rule” coming into play otherwise (Supplementary data).
3.3. Validity
3.3.1. Convergent validity
Tables 1 and S3–4 show that social and role functioningboth differed
across the spectrum of CHR current status speciﬁers. Pairwise ﬁndings
were also similar for social and role functioning. For patients with either
progressive or persistent status, functioning was signiﬁcantly lower
than for patients in either partial or full remission. Functioning did not
differ signiﬁcantly between progression and persistence statuses or be-
tween partial and full remission. Statistical power was b0.80 for partial
vs full remission (Table S3).
3.3.2. Discriminant validity
Table 2 shows how current status speciﬁers for CHR syndrome over-
lapped with those for DSM-IV Major Depression. Sixty-two percent of
cases in a knownCHR status did notmeet criteria for amajor depression
diagnosis. If these patients with no major depression diagnosis are notTable 1
Comparison of current status speciﬁersa on social and role functioning.
Speciﬁer measure Progression Persistence
Social functioning 6.17 ± 1.53a,b
(390)
5.96 ± 1.41c,d
(79)
Role functioning 6.08 ± 1.71a,b
(391)
6.23 ± 1.39c,d
(79)
Mean ± SD (n). Scales range from 1 to 10, with 10 indicating superior functioning, 7 mild pro
a–d groups with the same letter differ from each other p b 0.05.
a CHR speciﬁers and functioning each assessed at the same timepoint. Timepoints included ar
due to missing frequency ratings (Smf in Fig. 2) not shown.considered, along with the 39 in Table 2 whose major depression was
coded as status unspeciﬁed (296.20 or 296.30), Table 2 can be collapsed
into a 2 × 2 categorization: either in partial/full remission or not, for
each syndrome. Among unremitted CHR cases (n = 105), depression
was remitted in 58 (55%). Among remitted CHR cases (n= 18), depres-
sion was not remitted in 4 (22%). Kappa for agreement was 0.10 (less
than 0.40 poor (Fleiss, 1981)).
3.3.3. Predictive validity
Table 3 summarizes outcomes of CHR cases by current status at in-
terval start. These same data may be traced in Fig. 2. The proportion
converting to psychosis was signiﬁcantly higher in cases meeting pro-
gression criteria than in those meeting persistence criteria at interval
start and tended to be higher than in those meeting full remission
criteria (Table S5). Proportions converting in the other pairwise com-
parisons did not differ, but statistical power was low (Table S5).
3.4. Effects of treatment on conversion or progression after remission
Table 3 shows that four remitted patients then converted or met
criteria for progression over the next year. These outcomes generally
did not appear to be accounted for by discontinuation of treatment.
Treatment data were complete, and a medication or psychosocial treat-
ment present at remission was discontinued before conversion/pro-
gression in only one of these cases.
4. Discussion
This report presents nomenclature and criteria for syndromal diag-
nosis and current status assessment for clinical high risk (CHR) patients.
Data from theNAPLS-1 dataset provide partial support for the validity of
the current status designations.
4.1. Validity of the current status deﬁnitions
Taken together, the convergent, discriminant, and predictive validity
analyses are supportive of the validity of the CHR current status speci-
ﬁers as deﬁned in Fig. 1. These data must be interpreted cautiously,
however, because neither the convergent validity nor the predictive va-
lidity analyses fully distinguished each current status speciﬁer from all
others. The criteria in Fig. 1will need to be applied to additional samples
to evaluate validity fully. Persistence was distinguished from progres-
sion in the predictive validity analyses (conversion events in Table 3)
but not in the convergent validity analysis of functioning (Table 1).
The low functioning scores for patients in a persistent CHR status sug-
gest the need for longer follow-up to determine the likelihood of func-
tional improvement in this group. Partial remission was not
signiﬁcantly distinguished from full remission in either analysis, al-
though numerically patients in full remission did show higher function-
ing scores and lower conversion rates than those in partial remission.
The discriminant validity analysis in Table 2, which suggests substantial
independence between the course of the CHR syndrome and the course
of comorbid major depression, speaks to the validity of the CHRPartial remission Full remission F p
7.00 ± 1.53a,c
(34)
7.21 ± 1.41b,d
(65)
12.8 0.000
7.15 ± 1.68a,c
(34)
7.47 ± 1.28b,d
(64)
16.6 0.000
blems, 6 moderate impairment, and 1 extreme impairment.
e baseline, 12, or 24 months. Symptomatic patients unclassiﬁable into a CHR current status
Table 2
Current status speciﬁersa for CHR syndrome and DSM-IV Major Depression.
Current status Major depression
Severe Moderate Mild Partial remission Full remission Unspeciﬁed None Total
CHR syndrome Progressive 15 (5%) 18 (6%) 9 (3%) 19 (6%) 34 (11%) 27 (9%) 180 (60%) 302
Persistent 1 (2%) 4 (7%) 0 (0%) 4 (7%) 1 (2%) 9 (15%) 40 (68%) 59
Partial remission 1 (4%) 0 (0%) 0 (0%) 2 (8%) 2 (8%) 2 (8%) 18 (72%) 25
Full remission 2 (5%) 1 (2%) 0 (0%) 6 (14%) 4 (9%) 1 (2%) 29 (67%) 43
Total 19 23 9 31 41 39 267 429
a CHR syndrome andmajor depression each assessed at the same timepoint. Timepoints included are baseline, 12, or 24 months. Symptomatic patients unclassiﬁable into a CHR current
status due to missing frequency ratings (Smf in Fig. 2) not shown.
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speciﬁers.4.2. Utility of current status speciﬁcation
The deﬁnitions shown in Fig. 1 improve upon the SIPS assessment of
CHR syndrome in three ways. First, the deﬁnitions address a previous
limitation with the use of the SIPS. Previously, patients with continuing
but no longer progressive symptoms had to be classiﬁed as “not current-
ly CHR” whereas now they can be coded “CHR, currently persistent.”
There may be applications where the present classiﬁcation could be
used for baseline eligibility determination; for example, recruitment of
patients coded as “CHR, currently in full remission” could be useful as
entry criteria for clinical trial designs investigating whether treatments
sustain remission. Second, the deﬁnitions address ambiguities with the
use of the term “remission” of CHR syndrome over the past few years
(Simon and Umbricht, 2010; Addington et al., 2011; Velthorst et al.,
2011; Ziermans et al., 2011; Schlosser et al., 2012; Simon et al., 2012),
wherein it has not always been clear whether patients with persistent
symptoms qualiﬁed as remitted (because they no longer met the previ-
ously articulated CHR current presence criteria). Meta-analyses of re-
mission rates (Simon et al., 2013) would be facilitated by consistent
deﬁnition. In addition, remission from the less common BIPS and GRD
syndromes has not previously been addressed in the literature to our
knowledge. Third, the current status speciﬁers provide a richer descrip-
tion of the nonconverting patients. Future studies could determine
whether treatments differentially alter rates of continued progression,
persistence, or remission aswell as conversion rates, and ordinal regres-
sion analyses incorporating current statuses may be statistically more
powerful in detecting treatment effects than analyses of dichotomous
conversion vs non-conversion.
The present data suggest that most remissions are generally stable
over the next year (Table 3); however, a few patients did not remain
in remission but converted to psychosis or met criteria for progression.
Analyses of treatment data suggest that in at least some cases the loss of
sustained remission can be unrelated to discontinuation of previous
treatment. These observations are consistent with a previously recog-
nized course pattern wherein the original occurrence of progression
can sometimes constitute an “outpost syndrome” (Yung and McGorry,
1996) followed by remission and then later recurrence of illness. FutureTable 3
Twelve-month outcomes by CHR syndrome current status at interval start⁎.
Outcome interval start Psychosis Progression Persistence
Progression 40 (24%) 11 (10%)b 20 (23%)b
Persistence 0 (0%) 2 (26%)b 2 (21%)b
Partial remission 2 (14%) 0 (24%)b 0 (0%)b
Full remission 1 (5%) 1 (13%)b 0 (0%)b
Total 43 14 22
⁎ Interval starts either at baseline or at 12 months.
a Smf—patients with one or more positive symptoms in the CHR syndrome severity range, b
b Estimated percentages, calculated by estimating classiﬁcations for Smf cases based on result
estimation methods in data supplement).studies should focus on the course of remitted patients and on predic-
tors of sustaining remission.
4.3. Limitations
A number of limitations are recognized. The most important limita-
tion is the relative paucity of visits where patients could be classiﬁed in
persistent, partial remission, or full remission status, and especially the
limited number of one-year intervals beginning with those statuses.
This limitation applies to the convergent validity analysis in Table 1
and particularly to the predictive validity analyses in Table 3 and led
to low statistical power in both analyses (Tables S3 and S5). Larger sam-
ples are needed of patients in these current statuses. We underscore
that in retroﬁtting current status classiﬁcations to the NAPLS-1 data it
was never possible fully to apply the attribution criterion shown in
Fig. 1, since this criterion was not added to the SIPS formally until
after NAPLS-1 data collection ended. Site training in the SIPS did include
the understanding that attenuated positive symptoms due to another
disorder did not qualify for a CHR syndrome diagnosis, but there are
no ﬁelds in the NAPLS-1 dataset to document application of this criteri-
on. Another limitation is that symptom frequency ratings were often
not present in the NAPLS-1 dataset, due to their introduction into the
SIPSwith version 4.0 in 2003, while the sites' collection of data occurred
between 1998 and 2005. For intervals classiﬁable at start that required
frequency ratings to apply Fig. 1 criteria at interval end, the needed fre-
quency ratings were missing 50% of the time (Supplementary data).
Consequently the follow-up proportions of progression, persistence,
and partial remission statuses in Table 3 had partly to be estimated. It
also should be emphasized that inter-rater reliability remains to be
established.
Lastly, it is not yet clear for how long a diagnosis of CHR remains ap-
propriate after full remission has been achieved and continuously
sustained. Future research may permit recommendations for a deﬁni-
tion of recovery or for use of a term such as “past history of a CHR
diagnosis.”
4.4. Implications
Current status distinctions (progression, persistence, partial remis-
sion, full remission) for CHR patients appear to be valid and potentially
useful. Their application to additional samples may be warranted.Partial remission Full remission Smfa Total
29 (19%)b 41 (24%) 27 168
3 (24%)b 4 (29%) 3 14
1 (12%)b 7 (50%) 4 14
1 (7%)b 15 (75%) 2 20
34 67 36 216
ut who could not be classiﬁed because of missing symptom frequency ratings.
s in symptomatic caseswhose frequency ratingswere notmissing (please see Table S1 and
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